Clinical trials /

COMBAT Study: Botensilimab and Balstilimab

Not yet recruiting

This is an upcoming trial to study the effect of a botensilimab and balstilimab regimen in CRC patients with MRD after completing definitive standard-of-care therapy.

Study title

Microsatellite Stable Colorectal Cancer with Radiographic Occult Molecular Residual Disease Treated with Botensilimab (AGEN1181; Bot) plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study)

NCT ID: TBD

This is an upcoming trial to study the effect of a botensilimab and balstilimab regimen in CRC patients with MRD after definitive standard-of-care therapy.

Key Eligibility Criteria

  • Patients with confirmed colorectal adenocarcinoma

  • Patients must:

    • have undergone a complete surgical resection for stages II and III colon or rectal cancer and completed all planned adjuvant therapies

    • have no radiographic evidence of disease within 28 days before or after a positive ctDNA assay

Treatment

Drug: Botensilimab, a CTLA-4 inhibitor

Drug: Balstilimab, a PD-1 inhibitor

TBD

Agenus BOT + BAL